Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients

Table 6 Univariate and multivariate Cox regression analyses for recurrence-free survival in stage III colon cancers (n = 268)

Parameters	Univariate analysis			Multivariate analysis
Parameters	HR	95 % C.I.	P ^a	HR	95 % C.I.	P ^a
Gender (male vs. female)	1.96	0.881–4.367	0.099
Age (≥60 years vs. <60 years)	1.54	0.775–3.161	0.234
BMI (overweight vs. normal)	2.23	0.966–5.164	0.060
Tumor location (distal vs. proximal)	2.32	0.955–5.637	0.063
Pathology (mucinous vs. non-mucinous)	1.71	0.409–7.166	0.462
Differentiation (high grade vs. low grade)	1.41	0.428–4.619	0.575
T stage (T4 vs. T1, 2, 3)	2.97	1.284–6.865	0.011	2.50	1.065–5.854	0.035
N stage (N2 vs. N0, 1)	2.40	1.196–4.795	0.014	2.26	1.114–4.575	0.024
Microsatellite status (MSI-H vs. MSS + MSI-L)	1.06	0.254–4.451	0.933
Performance status (PS ≥ 1 vs. PS 0)	1.63	0.782–3.394	0.192
LINE-1 methylation (low vs. high)	3.36	1.287–8.781	0.013	3.50	1.338–9.126	0.011

BMI body mass index, MSS microsatellite stable, MSI-L microsatellite instability-low, MSI-H microsatellite instability-high, PS performance status
^aCox proportional hazard regression model, adjusted for other selected covariates

ISSN: 1868-7083